Phenotypic Skin Disease Models

For these models, a disease-like phenotype is simulated in healthy human skin biopsies sourced from cosmetic surgery procedures. Proprietary cocktails are used to stimulate disease pathways in these tissue samples, resulting in the upregulation of disease-relevant inflammatory mediators, such as Th17/IL-17 or IL-23 pathways. Once the disease phenotype has been achieved, your test compounds are added followed by an assessment of their anti-inflammatory effects.

  • Up to 30 punch biopsies can be obtained per tissue donor
  • Several compounds can be screened simultaneously
  • Biopsies can be cultured for up to 7 days 
  • A wide range of skin diseases can be modeled including psoriasis, atopic dermatitis, and acne

REPROCELL-04.06.18_0079

Image: Fresh skin tissue is used to create healthy punch biopsies for our phenotypic disease models.

icon-pdd-cro
Induced psoriasis model (Th17)

An assay using living skin that has been modified to produce a psoriasis-like phenotype via Th17 pathway activation including IL-17 induction.

icon-pdd-cro
Induced acne model (LPS)

This model uses skin that has been modified to produce an acne-like phenotype via stimulation with lipopolysaccharide (LPS).

icon-pdd-cro
Induced atopic dermatitis model

An assay using living skin that has been modified to produce an atopic dermatitis-like phenotype via Th2 pathway activation including IL-5, IL-13 and IL-22 induction.

icon-pdd-cro
Inflamed skin model (PHA)

This model uses skin that has been modified to produce a Th2-like phenotype via stimulation with phytohemagglutinin (PHA).